Search results
Results from the WOW.Com Content Network
Pomalidomide, sold under the brand names Pomalyst and Imnovid, [7] [8] is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. [ 7 ] Pomalidomide was approved for medical use in the United States in February 2013, [ 10 ] and in the European Union in August 2013. [ 8 ]
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone. [8] It is taken by mouth. [8]
Pomalidomide (3-aminothalidomide) was the second thalidomide analog to enter the clinic being more potent than both of its predecessors. [12] First reported in 2001, pomalidomide was noted to directly inhibit myeloma cell proliferation and thus inhibiting MM both on the tumor and vascular compartments. [13]
After years of clinical studies, the Food and Drug Administration approved pomalidomide, now branded as Pomalyst, for treatment of relapsed or refractory multiple myeloma on Feb. 8, 2013.
Oral Anti-Cancer Therapy REVLIMID ® (lenalidomide) Now Indicated as a Treatment for Patients with Rare Form of Blood Disease Treatment indicated for patients with transfusion-dependent anaemia ...
The answer is Pomalyst. Its parent has one of the longest and varied histories in the annals of medicine. Its sibling is a star raking in billions of dollars every year. And now it stands ready to ...
Palliative care is appropriate at any stage of multiple myeloma and can be provided alongside curative treatment. In addition to addressing symptoms of cancer, palliative care helps manage unwanted side effects, such as pain and nausea related to treatments. [144] [145]
As expected, the U.S. Food and Drug Administration granted approval on Feb. 8 for Celgene's Pomalyst in treating patients with multiple myeloma. Patients must have received at least two prior ...